BTA
Click for more information
0.00% 57.0¢ biota holdings limited

new drug on top of gsk weak defence

  1. koro
    9,950 Posts.
    lightbulb Created with Sketch. 205
    clock Created with Sketch.
    08/06/05
    11:42
    Post #: 939442
    gsk defence is in todays fin review,they seem to be contradicting themselves by saying sales were weak due to inhaler,BUT,the inhaler is great in 2001,and that they admit to under funding on promotion, pay up gsk while your still out of court,or else biota will be front page news when bird flu hits,e.g GSK HIDES RELENZA FROM THOSE MOST IN NEED.............................
    BTA Price at posting: 0.0¢ Sentiment: None Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

SXL Southern Cross says no to buy up of Australian Community Media assets
right-arrow Created with Sketch.
PH2 Pure Hydrogen to supply hydrogen-fuelled garbage truck to City of Newcastle
right-arrow Created with Sketch.
RMS Ramelius boosts WA gold portfolio with stake in Spartan
right-arrow Created with Sketch.
CMX ChemX Materials kicks off first stage works at WA high purity alumina pilot
right-arrow Created with Sketch.
LYC Lynas eyes first dysprosium, terbium HREE production in CY25
right-arrow Created with Sketch.
PDN Paladin flags up to 4.5Mlbs of uranium production in FY25 guidance
right-arrow Created with Sketch.
watchlist Created with Sketch. Add BTA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.